Latest stories on ICCM
IceCure Medical Wins China Regulatory Approval for ProSense® Tumor-Cryoablation System
TipRanks72 · bullishproduct/pr
IceCure Medical wins China approval for ProSense cryoablation system
Seeking Alpha67 · bullishproduct/pr
IceCure Medical granted regulatory approval to market ProSense in China
The Fly63 · neutralproduct/pr
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
PR Newswire63 · neutralproduct/pr
IceCure Medical Secures Exclusive Dutch Distributor for ProSense Cryoablation Systems
TipRanks63 · neutralproduct/pr
IceCure Medical announces distribution agreement with Scovas Medical
The Fly56 · neutralproduct/pr
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
StockTitan63 · neutralproduct/pr
IceCure Medical’s study for ProSense cryoablation approved by West Cancer Center
The Fly59 · neutralproduct/pr
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
PR Newswire59 · neutralproduct/pr
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript
Yahoo Top73 · bullishearnings
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript
The Motley Fool73 · bullishearnings
IceCure Medical highlights two publications supporting ProSense’s cryoablation
The Fly56 · neutralproduct/pr
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
PR Newswire63 · neutralproduct/pr
IceCure Medical Ltd Q2 2026 Earnings Call Summary
Yahoo Finance50 · neutralearnings
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
IceCure Medical Posts Higher H1 2026 Revenue but Wider Loss on Increased R&D Spend
TipRanks48 · neutralearnings
IceCure Medical GAAP EPS of -$3.17 misses by $1.65, revenue of $1.82M beats by $0.37M
Seeking Alpha34 · bearishearnings
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
PR Newswire67 · bullishearnings
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
PR Newswire50 · neutralgeneral
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
PR Newswire63 · neutralproduct/pr
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
PR Newswire67 · bullishproduct/pr
Brazil Sees Surge in ProSense Cryoablation Adoption After FDA Nod—Key Studies Aim to Drive Further Growth
MarketChameleon67 · bullishproduct/pr
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
PR Newswire63 · neutralproduct/pr